177 related articles for article (PubMed ID: 9267820)
1. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
4. Concordant p53 and mdm-2 protein expression in vulvar squamous cell carcinoma and adjacent lichen sclerosus.
Carlson JA; Amin S; Malfetano J; Tien AT; Selkin B; Hou J; Goncharuk V; Wilson VL; Rohwedder A; Ambros R; Ross JS
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):150-63. PubMed ID: 11396633
[TBL] [Abstract][Full Text] [Related]
5. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
6. Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma.
Morgan RJ; Newcomb PV; Hardwick RH; Alderson D
Eur J Surg Oncol; 1999 Aug; 25(4):364-7. PubMed ID: 10419705
[TBL] [Abstract][Full Text] [Related]
7. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx.
Pignataro L; Capaccio P; Pruneri G; Carboni N; Buffa R; Neri A; Ottaviani A
J Laryngol Otol; 1998 May; 112(5):455-9. PubMed ID: 9747474
[TBL] [Abstract][Full Text] [Related]
9. Abnormal expression of MDM-2 in breast carcinomas.
Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
[TBL] [Abstract][Full Text] [Related]
10. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases.
Emanuels AG; Koudstaal J; Burger MP; Hollema H
Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975
[TBL] [Abstract][Full Text] [Related]
11. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
12. MDM-2 protein is expressed in different layers of normal human skin.
Dazard JE; Augias D; Neel H; Mils V; Marechal V; Basset-Séguin N; Piette J
Oncogene; 1997 Mar; 14(9):1123-8. PubMed ID: 9070662
[TBL] [Abstract][Full Text] [Related]
13. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions.
Ahomadegbe JC; Barrois M; Fogel S; Le Bihan ML; Douc-Rasy S; Duvillard P; Armand JP; Riou G
Oncogene; 1995 Mar; 10(6):1217-27. PubMed ID: 7700647
[TBL] [Abstract][Full Text] [Related]
14. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
15. Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation.
Mayo LD; Berberich SJ
Oncogene; 1996 Dec; 13(11):2315-21. PubMed ID: 8957072
[TBL] [Abstract][Full Text] [Related]
16. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors.
Yanamoto S; Kawasaki G; Yoshitomi I; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Nov; 94(5):593-600. PubMed ID: 12424454
[TBL] [Abstract][Full Text] [Related]
17. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
19. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
[TBL] [Abstract][Full Text] [Related]
20. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx.
Nadal A; Jares P; Cazorla M; Fernández PL; Sanjuan X; Hernandez L; Pinyol M; Aldea M; Mallofré C; Muntané J; Traserra J; Campo E; Cardesa A
J Pathol; 1997 Oct; 183(2):156-63. PubMed ID: 9390027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]